AxoGen(US:AXGN)2026-02-24 21:24Financial Performance - Revenue for the year ended December 31, 2025, was $225,208, an increase of $37,870, or 20.2%, compared to $187,338 for 2024[399] - Gross profit for 2025 was $167,353, an increase of $25,376, or 17.9%, compared to $141,977 for 2024, with a gross margin of 74.3%[402] - Net loss for 2025 was $15.7 million, or $0.34 per share, compared to a net loss of $10.0 million, or $0.23 per share for 2024[399] - Total costs and expenses for 2025 were $175,202, a 20.6% increase from $145,264 in 2024, driven by higher sales and marketing costs[403] Cash Flow and Investments - Cash and cash equivalents, restricted cash, and investments increased to $45.5 million as of December 31, 2025, up from $39.5 million in 2024[399] - Net cash provided by operating activities was $812 for 2025, a decrease from $4,535 in 2024, primarily due to unfavorable changes in working capital[410] - Net cash used in investing activities was $5,317 for 2025, compared to $10,297 for 2024, reflecting an increase in proceeds from the sale of investments[411] - Net cash provided by financing activities increased by $8,209, or 358%, to $10,499 compared to $2,290 for the year ended December 31, 2024, primarily due to an increase in proceeds from stock options and Employee Stock Purchase Plan purchases[412] Debt and Obligations - As of December 31, 2025, the outstanding principal amount of loans under the Credit Facility was $50,000, with interest calculated at 7.5% plus the greater of Adjusted SOFR or 2.0% (11.59% as of December 31, 2025)[414][439] - Total contractual obligations as of December 31, 2025, amounted to $91,288, including $50,000 for the Credit Facility principal and $10,427 for interest payments[415] Equity and Capital Requirements - The company received net proceeds of $133,338 from an equity offering, which were used for the early payoff of the Credit Facility and for working capital and capital expenditures[436] - The company expects future capital requirements to depend on factors such as expanding the customer base and introducing new products, with potential dilution from additional equity securities[413] - The company sold 4,600,000 shares at a public offering price of $31.00 per share, closing the offering on January 23, 2026[435] Risk Management - The company recorded a derivative liability of $3,886 as of December 31, 2025, with a potential $600 effect on fair value if the discount rate changes by 1%[423] - The company reserved $2,202 for potential losses relating to inventory as of December 31, 2025, which could affect future operating results if product demand is less favorable than projected[420] - As of December 31, 2025, $35,048 of cash and cash equivalents was in excess of FDIC limits or not FDIC-insured, exposing the company to credit risk[441] - There have been no material losses on accounts receivable, with credit risk managed through evaluations and monitoring procedures[443] - The company has minimal exposure to foreign currency exchange risk as international revenues are denominated in U.S. dollars[444] Market and Coverage - Coverage for nerve repair procedures increased to approximately 19.8 million lives in 2025, with commercial payer coverage exceeding 65%[399] - Effective January 1, 2026, CMS established a new Level 3 Nerve Procedure Code, increasing Avance facility reimbursement by 40% year-over-year to $9 for hospital outpatient procedures[399] - The company aims to deepen its presence in high-potential accounts, particularly Level 1 trauma centers and academic hospitals, to drive growth in nerve repair indications[398] Product and Investment Strategy - Cash is primarily invested in money market accounts and U.S. Treasuries, focusing on cash preservation as the main objective[442] - The product portfolio is available in multiple countries including the U.S., Canada, Germany, the U.K., and Spain[444] - Stock-based compensation expense could change by $541 if the payout range of unvested PSUs changes by 50 basis points as of December 31, 2025[432]